Significant reductions seen in RSV-related infections, RSV-related hospitalizations for three monoclonal antibodies versus placebo
Your search for supplemental oxygen returned 10 results
The studies evaluated routine clinical practice data from more than 800 hospitals in the US.
Current evidence indicates that a 6mg dose of dexamethasone daily is effective for improving COVID-19 outcomes among patients receiving supplemental oxygen.
Investigators developed and validated a machine learning tool providing an early indication of disease progression in community-acquired pneumonia.
Lower average oxygen delivery rates seen in association with Asian, Black, Hispanic versus White race, ethnicity
Investigators report findings from a secondary analysis of the DARE-19 trial, which compared dapagliflozin with placebo in patients hospitalized with COVID-19.
Shortly after an EUA was issued, Genentech announced that tocilizumab (marketed under the brand name Actemra) was in shortage.
No significant difference versus placebo observed for hospitalized patients with COVID-19 receiving noninvasive supplemental oxygen
The EUA was issued based on 4 randomized controlled clinical trials that evaluated the efficacy and safety of Actemra in more than 5500 hospitalized patients with COVID-19.
Findings showed that the trial did not meet statistical significance on the primary endpoint.